Abstract
INTRODUCTION Our understanding of the impact of astrocytes in Alzheimer’s disease (AD) is hindered by limited astrocyte-specific data from AD and mild cognitive impairment (MCI).
METHODS An astrocytic gene cluster was generated from RNAseq data of isolated healthy human brain cells using a cell-type enrichment score and clustering. The astrocytic cluster was localized in whole-brain transcriptomes from three independent cohorts totaling 766 individuals with MCI or AD, and controls. Changes in astrocytic gene expression were analyzed by gene set and principal component analyses.
RESULTS Individuals with the same clinical diagnosis, including controls, were molecularly heterogeneous. Astrocytes in MCI and AD showed downregulation of ‘mitochondria’ and ‘endomembrane system’, and upregulation of ‘stress responses’, ‘plasticity’, and ‘perisynaptic astrocyte processes’/’gliotransmission’.
DISCUSSION Astrocytes undergo a profound transcriptional change in MCI and AD, affecting organelles and astrocyte-neuron interactions. We posit that therapies preventing organelle dysfunction in astrocytes may protect neural circuits in AD.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study analyzed publicly available data and was not a clinical trial.
Funding Statement
This work was supported by Fundacio Marato-TV3 (grant number 201414-30), and Grup de Recerca en demencias: Sant Pau SGR2017547, Generalitat de Catalunya (E.G.), by funds from the Coins for Alzheimer's Research Trust (L.B.W.) and startup funds from the Woodruff School of Mechanical Engineering at Georgia Tech (L.B.W.). L.D.W. and A.F.P were supported in part by the National Institutes of Health Cell and Tissue Engineering Biotechnology Training Grant (T32-GM008433). CNRS, CEA and France Alzheimer (C.E.). The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.synapse.org). Study data were provided by the following sources: The Mayo Clinic Alzheimers Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimers Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Founda-tion. Study data includes samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Ser-vices (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. Study data were also provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). ROSMAP data can be requested at www.radc.rush.edu.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work used publicly available de-identified transcriptomic data and thus did not require IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos